Rapidly Growing Prestige Brands Still Positioned For OTC Pickups
This article was originally published in The Tan Sheet
Executive Summary
The company says it successfully integrated the OTC portfolio acquired from GlaxoSmithKline and is using free cash flow to trim its debt load in the wake of the debt-financed $660 million deal. Prestige reported Q1 net sales up 54.7%, including 4.2% organic growth in OTC health care.
You may also be interested in...
Genomma Refuses To Raise Price, Drops Prestige Bid
Genomma drops its unsolicited offer because it was unwilling to meet Prestige’s demand for a higher price. The Mexican firm said it secured funding and met other milestones Prestige insisted on.
Sales & Earnings In Brief
GlaxoSmithKline and Prestige Brands report financial results in the wake of their OTC brands deal; Allegra boosts Sanofi’s consumer business; lower private label sales hit NBTY; USANA plots North American growth.
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.